Moreover, we identified IL-15 as a signal capable of driving the de novo acquisition of NKp30 and initiating a CD8+ T cell reprogramming toward innate.23 This cell population endowed with both the CD8+ T cell and NK cell tumor recognition principle, could hold promise for immunotherapeutic approaches against cancer. The gene discussed is NCR3; the disease is neoplasm.